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Abstract
Gastric carcinoma (GC) develops in only 1%-3% of 
Helicobacter pylori (H. pylori ) infected people. The 
role in GC formation of the bacterial genotypes, gene 
polymorphisms and host’s factors may therefore be 
important. The risk of GC is enhanced when individuals 
are infected by strains expressing the oncoprotein CagA, 
in particular if CagA has a high number of repeats 
containing the EPIYA sequence in its C’-terminal variable 
region or particular amino acid sequences flank the 
EPIYA motifs. H. pylori  infection triggers an inflammatory 
response characterised by an increased secretion of 
some chemokines by immunocytes and colonised 
gastric epithelial cells; these molecules are especially 
constituted by proteins composing the interleukin-
1beta (IL-1β) group and tumour necrosis factor-alpha 
(TNF-α). Polymorphisms in the promoter regions of 
genes encoding these molecules, could account for high 
concentrations of IL-1β and TNF-α in the gastric mucosa, 
which may cause hypochlorhydria and eventually GC. 
Inconsistent results have been attained with other 
haplotypes of inflammatory and anti-inflammatory 
cytokines. Genomic mechanisms of GC development are 
mainly based on chromosomal or microsatellite instability 
(MSI) and deregulation of signalling transduction 
pathways. H. pylori  infection may induce DNA instability 
and breaks of double-strand DNA in gastric mucocytes. 
Different H. pylori  strains seem to differently increase 
the risk of cancer development run by the host. Certain 
H. pylori  genotypes (such as the cagA  positive) induce 
high degrees of chronic inflammation and determine 
an increase of mutagenesis rate, oxidative-stress, 
mismatch repair mechanisms, down-regulation of base 
excision and genetic instability, as well as generation 
of reactive oxygen species that modulate apoptosis; 
these phenomena may end to trigger or concur to GC 
development.
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Core tip: CagA and the cagA types may play different 
roles in the intestinal and diffuse histotypes of gastric 
carcinoma (GC); The current criteria of Helicobacter 
pylori (H. pylori ) strain classification based on their 
carcinogenic potential gave rise to confusion and should 
be unified. The possible role of inflammatory cytokine 
haplotypes in GC development should be reassessed 
taking into account some host’s factors, the most im-
portant being different ethnic origin. Infection by the 
cagA  positive H. pylori  genotype may determine an 
increased inflammatory response and a consequent 
enhancement of mutagenesis rate, oxidative-stress, 
reactive oxygen species generation, dysfunction of DNA 
repair mechanisms, genetic instability and resultant high 
risk of GC development.
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INTRODUCTION
Gastric carcinoma (GC) is the second most frequent 
cause of death from cancer worldwide and the most 
common example of a neoplasia developing on a ground 
of a chronically inflamed mucosa. GC has also another 
record: It is the only known malignant tumour that can 
develop as a consequence of a chronic bacterial infe­
ction[1]. In 1994, the International Agency for Research 
on Cancer classified the organism responsible for 
the infection, Helicobacter pylori (H. pylori) ­ a Gram 
negative, microaerophilic and spiral-shaped species 
that finds its habitat in human stomachs - as a definite 
carcinogen to humans (Group 1): The connection of H. 
pylori with gastric cancer was considered similar to that 
existing between the cigarette smoke and lung cancer[2].
The bacterium H. pylori: Not all the strains are alike
It soon became clear, however, that such comparison 
was reductive and too simplistic, especially because 
the ability of these bacteria to trigger a neoplasm is 
not limited to the inflammatory and immune response 
to the infection that they cause, but it also resides in 
a series of bacterial factors capable of prompting and 
modulating the carcinogenic process[3].
As is the case for all diseases, also GC develops from 
the concomitance of three factors: The etiological agent, 
the host and the environment. Of course, many other 
factors may occur; for example, the cancer histological 
variant, the degree of differentiation of the neoplasia 
etc.[4]. Regarding the etiological agent, H. pylori, there 
are many indications that not all strains are equivalent 
in their carcinogenic potential and that those expressing 
an immunodominant peptide determinant called CagA 
(cytotoxin associated gene A), are endowed with an 
increased inflammatory and carcinogenic potential[5-9]. 
A first point has therefore been established: Strain geno-
mic diversity corresponds to different ability to promote 
cancer. The possibility that a bacterial factor (CagA) 
could trigger or concur to the development of GC is one 
of the most important scientific achievements following 
the isolation of H. pylori.
The importance of being called CagA positive 
It is worthwhile mentioning the steps that paved the 
way to the discovery of CagA. At the end of the 80ies, 
Leunk et al[10] first proposed that H. pylori should not 
be considered a clonal pathogen, as a relevant pro-
portion of isolates produce a vacuolating toxin, which 
could account in part for the gastric mucosa damage 
observed in infected individuals. Afterward, our group 
suggested that infection by cytotoxic strains increased 
the risk of developing peptic ulceration[11] and that 
virtually all cytotoxic isolates also secreted a 120 kDa 
highly immunogenic protein, later called CagA[12]. In 
1992, Crabtree et al[13] demonstrated, through ex vivo 
experiments, that such a protein was produced either 
by the bacteria isolated in culture and also by the 
organisms colonizing the gastric epithelium: Gastric 
antral explants of patients with GC and other pathologies 
were cultured in vitro for a few days; the bacteria that 
colonized the mucosa kept on secreting this peptide, 
which could lastly be detected in the culture medium 
by using immunological methods[13]. In 1993, the same 
team established, for the first time, the existence of 
a relationship between infection by strains expressing 
the 120 kDa protein and GC development[14]. Their 
observations were important also because these re­
searchers found anti-120 kDa protein mucosal IgA 
antibodies even in the absence of systemic IgG to this 
protein and, in some patients, also in cases with urease 
negative biopsies (false negatives). In the same year 
(1993), the gene encoding for the 120 kDa protein 
was cloned, sequenced and called cagA due to the 
strict association of protein expression with cytotoxin 
production[5]. As a result of these findings, the number 
of studies dealing with the characterisation of CagA and 
its potential carcinogenicity increased exponentially and 
results lead to the common conclusion that such peptide 
is a major factor in gastric carcinogenesis.
CagA is the product of the homonymous gene placed 
at the end of the so-called pathogenicity island (PAI) 
cag, a fragment of DNA encompassing an approximately 
40 kb cluster of genes involved in virulence. In the 
field of bacteriology there are numerous examples of 
PAIs harboured by diverse bacterial species or their 
virulent variants, whether they are human (Bordetella 
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pertussis, Escherichia coli, Salmonella enterica, etc.) or 
plant pathogens (Agrobacterium tumefaciens). In some 
species, PAI genes cooperate to translate effectors 
(mainly proteins) endowed with carcinogenic potential 
inside colonised cells. In H. pylori, such determinant 
is CagA. Similarly, A. tumefaciens exploits the Type Ⅳ 
secretion system vir to translate a single­stranded form 
of T-region (T-strand) coated by the ssDNA-binding 
protein VirE2 (T­Complex) into the host’s vegetal cell 
nuclei. Once inside the nucleus, the T-strand can be 
converted in a double-stranded form (T-DNA), whose 
expression causes an uncontrolled host cell proliferation 
and tumour development[15].
Epidemiological and genomic studies suggest that 
the development of GC is a possible consequence of 
infection by strains expressing CagA[1,8,9,14,16]. In effects, 
using Mongolian gerbils infected experimentally, it 
was shown that only CagA positive (CagA+) H. pylori 
strains were able to induce stomach tumours[17]. In 
addition, a study of our group revealed that, while 
virtually all patients with intestinal histotype of GC had 
serum antibodies to CagA, the prevalence of anti-CagA 
antibodies in patients with the diffuse GC variety was 
similar to that observed in infected controls without 
neoplasia[16]. These data were confirmed by the results 
of an epidemiological study: The overall GC risk in 
infected people lacking anti-CagA antibodies (CagA-) 
was increased, but in non-significant way; in any case, 
CagA- H. pylori infection was associated with the growth 
of the diffuse variety of GC (with an OR of 9.0)[8].
It therefore seems that infections by CagA+ strains 
expose people to an increased risk of GC respect to 
infections by CagA- H. pylori strains, which can only 
be associated with the diffuse histotype. In effect, 
things work slightly differently. In a recent study, we 
examined for the presence of cagA up to 25 distinct, well 
separated colonies per patient with GC; even though 
only individuals with diffuse histotype GC harboured 
cagA negative (cagA-) organisms, in all cases patients 
were also infected by at least one cagA positive (cagA+) 
strain[18]. These observations do not corroborate the 
supposed propensity of strains lacking cag PAI to concur 
to diffuse GC development and suggest that, for a better 
comprehension of the role played by cagA in the histolo­
gical variety of GC, many colonies per patient should be 
examined genomically.
CagA phosphorylation by mucocytes: Like shooting 
oneself in the foot
H. pylori organisms expressing CagA differ in their 
carcinogenic potential. Let us have a look at the mec-
hanisms that may influence the ability of such a protein 
to trigger and/or concur to GC formation. CagA, following 
colonisation, is translated into the gastric epithelial cells 
through a conjugative apparatus encoded by the cag 
PAI genes upstream cagA; then, a portion of intracellular 
CagA is phosphorylated by numerous kinases, members 
of the host cell Src family (such as Yes, Lyn, Fyn and 
c-Src,) at the EPIYA C’-terminal site (Glu-Pro-Ile-Tyr-
Ala) motif of tyrosine[19]. Phosphorylated CagA physically 
interacts with the oncogenic tyrosine phosphatase 
SHP-2 (Src homology phosphatase 2), modifying cellular 
functions and altering mammalian signal transduction 
machineries. SHP-2, in fact, is implicated in the regu-
lation of cell adhesion, spreading and migration. In this 
manner, phosphorylated CagA causes deregulation of 
SHP-2 and induces abnormal proliferation, as well as 
movement of cells of the gastric epithelial layer, activates 
mitogenic signalling and disturbs host­signalling 
routes[20]. All these events may also predispose cells to 
accumulate multiple genetic and epigenetic alterations 
involved in gastric tumorigenesis[21].
Unphosphorylated CagA, on the other hand, interacts 
with the tumour suppressor protein of p53 (ASPP2), 
which also exert an apoptosis­stimulating activity[22]. In 
normal conditions, following genotoxic and oncogenic 
stimuli, ASPP2 associates with tumour suppressor p53, 
activates it and induces apoptosis. After interaction 
with CagA, cytosolic p53 is recruited by ASPP2 and 
subsequently is degraded by an enzyme complex 
that control cell-cycle and apoptosis, the proteasome. 
As a consequence, the apoptotic response of host 
cells is inhibited. In other words, unphosphorylated 
CagA takes control of ASPP2 and subverts the tumour 
suppressor pathway of apoptosis­stimulating protein 
p53 with consequent promotion of cell survival and cell 
transformation[20-22]. The resultant abnormal prolifer-
ation of gastric epithelial cells may contribute to GC 
development.
Individual CagA proteins have different biological 
activity and tumorigenic potential: When size matters
H. pylori strains secreting CagA protein endowed 
with increased biological activity can be considered 
more virulent and even more closely associated with 
gastric cancer. At the end of 90’s, the group of Graham 
discovered the ability of distinct CagA proteins to perturb 
cellular functions might vary in different isolates[23]. The 
CagA C’-terminal region contains one or more repeats 
of the same amino acids in sequence (Glu­Pro­Ile­Tyr­
Ala, or EPIYA)[5]; the teleonomic significance of such 
phenomenon reflects the bacterial strategy to generate 
antigenic diversity, which may protect the organisms 
from the immune response. The number of EPIYA motifs 
correlates with the size of the cagA variable region. 
Yamaoka et al[23] basing of the amplicon sizes obtained 
with primers encompassing the entire cagA variable 
region, classified H. pylori isolates in cagA structural 
types A, B, C and D (amplicons characterising types 
B and D have the same size and can be differentiated 
by sequencing). Strains with the cagA structural type 
C have the highest number of EPIYA phosphorylation 
motifs and were isolated significantly more often from 
patients with GC[23], confirming a previous observation 
that individuals with GC are infected by strains ex­
pressing CagA proteins with higher mass[24]. The incr-
42WJGO|www.wjgnet.com January 15, 2016|Volume 8|Issue 1|
Figura N et al . H. pylori  and gastric carcinoma
size and subtype B those with the greatest one. Specific 
cagA subtype A strains (those yielding amplicons of 
intermediate size) were predominantly isolated from 
Chinese compared to Malays and Indians patients. Since 
Chinese patients have the highest risk of GC disease 
respect to the other ethnic groups, these investigators 
concluded that cagA subtyping could be used as a 
clinical biomarker for severe outcome of infection. Such 
statement, however, was based on indirect observations 
because they did not examine strains from GC cases[30]. 
In 2002, Higashi et al[20] observed that the ability 
of CagA secreted by different strains to disturb host-
cell functions can be influenced by the strength of 
SHP-2 binding activity, which was increased in H. pylori 
strains obtained from patients living in East Asian areas 
(Japan, Chorea and China) respect to those isolated 
from patients of Western countries (Europe, America, 
and Australia). In addition to the number of EPIYA 
repeats, it was also found that polymorphism in the 
nucleotide sequence flanking the regions that encode 
EPIYA could affect the potential of different H. pylori 
strains to promote gastric carcinogenesis[31]. According 
to the geographic regions in which strains are isolated, 
it is possible to characterise the cagA variable region on 
the basis of the number and the type of sequences. The 
Western H. pylori CagA has two segments of 32 and 40 
amino acids flanking EPIYA (EPIYA-A and EPIYA-B types) 
and one to three 34 amino acid EPIYA-C segments 
(A-B-C type CagA)[21]. Eastern CagA presents EPIYA-A 
and EPIYA-B segments, but none of the EPIYA-C frag-
ment; it has instead one copy alone of a segment 
called EPIYA-D, which represents the main tyrosine 
phosphorylation site[20,21]. In western strains, the major 
site of tyrosine phosphorylation of CagA is EPIYA-C; 
the tyrosine residues that characterize EPIYA-A and 
EPIYA-B segments are phosphorylated only very weakly. 
Such a difference in phosphorylation degrees resides in 
the diverse consensus high­affinity binding sequence 
for the SH2 domains of SHP-2. Unlike what happens 
for EPIYA-D type, the western EPIYA-C type of CagA 
differs by a single amino acid from the consensus SHP-2 
binding sequence[21]. 
In conclusion, the carcinogenic potential of H. pylori 
varies according to the number and the cagA structural 
types of the EPIYA flanking regions. East Asian CagA 
has an increased virulence and a strong ability to trigger 
GC, while, among western isolates, more carcinogenic 
are the helicobacters with two or three CagA EPIYA-C 
sites. This was also demonstrated by a study in which 
it was observed that 83.3% of GC strains possessed 
multiple EPIYA-C sites, vs only 5.2% of strains isolated 
from patients with chronic gastritis only (controls)[32]. 
Often, cagA+ strains are also isolated from patients 
with duodenal ulcer (NF personal observation). This 
finding may create confusion, because is common 
knowledge that patients with duodenal ulcer are like 
protected from GC development; however, the results 
of a recent study[33] showed that the increased virulence 
eased carcinogenic potential of the cagA structural type 
C was also confirmed by another study of the same 
group, which showed that patients infected by H. pylori 
with this cagA genotype run a higher risk of developing 
gastric mucosa atrophy, a precancerous condition[25].
Now, it should be highlighted that the primers used 
in these studies to amplify the cagA variable region were 
designed on oriental (Japanese) strains, which may 
differ from western strains in the nucleotide sequence 
encoding the C’­terminal variable region[26]. Probably for 
this reason not all surveys on the same subject have 
confirmed the Yamaoka et al[23,25]’s findings. In an initial 
study of our group, in which we used the Yamaoka’s 
primers to amplify the cagA variable region of Italian 
strains[27], we sometime obtained amplicons shorter 
than the PCR product that characterises the cagA 
structural type A; strains producing such amplicons, 
which presented a deletion of about 100 bp respect to 
cagA type A, were named type A(I), with (I) standing 
for Italy, because, as far as we know, similar cagA 
structural variety had not previously been described. 
In a more recent investigation, we observed similar 
proportions of the various cagA structural types in 
Italian H. pylori organisms isolated from GC cases and 
from controls (patients without neoplasia, with chronic 
gastritis only)[28]. In addition, in the control subjects, 
we frequently detected strains with the cagA structural 
type A(I). The increased prevalence of such a cagA type 
in individuals without GC prompted us to hypothesise 
that the reduced dimensions of the encoded CagA 
may decrease the ability of these bacteria to trigger a 
neoplastic process. As a matter of fact, the capability of 
CagA of binding SHP-2, and therefore of disturbing the 
various cellular functions, is regulated by the amounts 
of tyrosine phosphorylation site sequences, i.e., the 
CagA size[20]; therefore, the shorter the protein, the less 
numerous are the EPIYA repeats that undergo phos-
phorylation and the lower is the carcinogenic potential of 
strains.
The employment of primers proposed by Yamaoka 
et al[23] to amplify the cagA variable region of western 
strains has sometimes led to results similar to those of 
the Japanese researchers: South African researchers, 
for instance, have confirmed that patients with GC have 
an increased prevalence of strains with type C CagA[29]. 
Investigations dealing with this important subject, 
however, are not numerous; in addition, sometimes they 
attained different conclusions and have even contributed 
to create confusion in this subject. Malaysian authors, 
for instance, using the primers designed by Yamaoka 
et al[23], determined the presence and distribution of 
cagA variants among different ethnic groups and various 
gastroduodenal diseases[30]. They obtained three types 
of amplicons and named the cagA subtypes with capital 
letters, A, B and C (like did Yamaoka et al[23]), but, just 
to complicate this topic further, they used a different 
criterion (respect to that of the previous study) and 
called subtype C the strains with the smallest amplicon 
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of strains with CagA EPIYA-C type augmented the 
risk of gastric cancer and not peptic ulceration. Some 
studies diverge from these conclusions: Findings of 
an investigation carried out in Colombia suggest that 
polymorphic CagA proteins, based on sequences 
flanking the EPIYA motifs, are not clearly associated 
with the outcome of the infection[34]. The absence of 
association between the CagA polymorphisms and 
pathogenesis of gastroduodenal diseases could be due 
to geographic factors and/or the host’s genetic features 
and environmental determinants.
In conclusion, the results of this kind of investigations 
are potentially useful, but the confusion existing in this 
field ought to be rectified and the different researchers 
should use the same criteria for classification. The 
various groups, however, have reached a common con-
clusion: Not all the strains are alike in their carcinogenic 
potential.
NOT ALL PATIENTS ARE ALIKE: THE 
ROLE OF THE HOST’S INFLAMMATORY 
CYTOKINE HAPLOTYPES IN GC 
DEVELOPMENT
Background
The hypothesis that human genetic polymorphisms may 
affect predisposition to GC has recently been explored. 
GC develops in only 1%-3% of H. pylori infected indivi­
duals, which suggests that the host background matters 
in this neoplasia. Several pro-inflammatory cytokines 
are produced by the immune system against H. pylori; 
among them, IL-1β is of paramount importance; a 
second one is tumor necrosis factor-alpha (TNF-α); 
both of them are closely related to epithelial injury and 
gastric hypochlorhydria[35,36]. At low concentrations, 
TNF-α enhances the protective inflammatory response; 
at high concentrations, it can injure the gastric mucosa 
and cause severe pathology[37]. IL-1β increases the 
surface molecule expression on endothelial cells, causing 
leukocytes to adhere; IL­1β also induces the production 
of macrophage chemokines leading to neutrophil acti­
vation. Recent investigations have revealed that there 
is a genetic regulation of the host cytokine response 
to inflammatory stimuli. Genomic variants of IL-1β 
and TNF-α  were shown to correlate with the clinical 
outcomes of tumors, including GC[38,39]. The IL-1β gene 
cluster is polymorphic, with some alleles present at 
relatively high frequencies. Particular IL-1β haplotypes 
enhance the risk of GC because they induce an over 
expression of its product in the stomach, causing chronic 
hypochlorhydria, which in turn may produce gastric 
atrophy and, eventually and in the presence of other 
risk factors, GC[40]. In addition, patients with a particular 
haplotype of the gene that encodes IL-RA (receptor 
antagonist) have an elevated risk of developing GC. IL-
RA is an anti-inflammatory cytokine, which is a comp-
etitor for IL­1β receptors, thus regulating the possible 
harmful effects of IL­1β receptors. 
The role of the host in GC development could be 
important because the inflammatory response to 
infections varies from patient to patient due to the gene 
polymorphism of inflammatory and anti­inflammatory 
cytokines. Many studies have been performed in the last 
15 years, with the scope of identifying a genetic marker 
that can determine whether or not people carrying the 
infection might be at risk of developing GC in H. pylori 
infected patients[41-59]. Such a marker is still lacking, and 
we shall try to explain some of the reasons underlying 
this problem.
The association between chronic inflammation and 
cancer has been known since Virchow, in 1864, wrote 
that cancer would arise from sites of inflammation: 
“Chronic irritation which is manifested by a chronic 
inflammation is a key promoter of cancer” (Quoted by 
Balkwill and Mantovani[60]). Individual cytokines were 
specifically examined, in particular the proinflammatory 
ones. The most well known cytokine is IL-1, along with 
its receptor (IL-1R) and the antagonist of this receptor 
(IL-1RA); all of them share the chromosomal location 
of the IL-1 gene family (namely 2q13-14). IL-1β has 
thus been established as an important regulator of 
carcinogenesis, characteristic of interactions between the 
host and environment[54].
IL-1β  haplotypes
The IL-1β gene displays considerable polymorphism[54]; 
the presence of C to T transition was frequently 
found either in the promoter region at positions ­511 
(CT; dbSNP: rs16944), at position -31 (TC; dbSNP: 
rs1143627) or in the coding region at position +3954 
(CT; dbSNP: rs1143634) base pairs from the origin of 
transcription. The two single nucleotide polymorphisms 
(SNPs) within promoter region are in linkage disequili-
brium. The IL-1β -31 TC substitution disrupts a TATA-
box motif; this leads to several transcription factors 
having altered binding affinities, resulting in modified IL-
1β transcription. The IL-1β +3954 CT substitution is a 
synonymous SNP. It was demonstrated in vitro that the 
C to T transition at positions -511 and +3954 correlated 
with elevated IL­1β levels as a result of lipopolysacc­
haride (LPS)-stimulated IL-1β protein secretion[54].
The paradigm of all subsequent studies regarding GC 
with respect to different haplotypes in cytokines was the 
focus of the paper by El-Omar et al[38], who noted for 
the first time that the presence of two polymorphisms 
(rs16944 and rs1143627) in the promoter region of 
the IL-1β gene, identified an increased risk of hypochlor-
hydria, as a result of H. pylori infection and GC[38]. These 
polymorphisms determine an increased secretion of IL­
1β[61], a conclusion confirmed and generalized by later 
reports[62]. The discrepancy of results reached in different 
papers was clarified only after several years, once taking 
into account the origin of the population and the type 
of GC. Overall, more than 90 publications dealt with 
this issue, over half of them from Asia, and a single one 
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from North America, a clear indication of the perceived 
relevance of this neoplasia in the different populations.
Since the single studies are extremely inconsistent 
and, if taken alone, contribute little to the general 
overview, we opted for reporting from selected meta-
analyses in this paper. Meta-analyses accrued from time 
to time in a number of studies originating from different 
countries, which is one of the main causes of contradic-
tory results, as well as from different histological variety 
of stomach malignancies, another cause of strong 
difference in results[41-59].
The overall findings from the large amount of efforts 
can be summarized as follows:
(1) IL-1β receptor antagonist (IL-1β RA) polymor­
phism: The most credible and consistent association of 
peculiar genetic variation with GC was found for IL-1β 
RA haplotypes. Four alleles, numbered 1 to 4, are widely 
present in the general populations. People carrying the 
homozygous allele 2/2 (IL-1β  RN2) were found to be 
at higher risk of developing cancer among non-Asian 
populations. Moreover, the analysis of GC patients 
altogether, without stratifying according to histological 
type, anatomic site or country of origin, showed that 
patients carrying homozygous allele 2, or IL-1 RN2 had 
an increased risk of developing cancer, which was statisti-
cally significant. The risk was found both in cardia and 
non-cardia types of neoplasia. A possible explanation 
for the risk stems from the high IL­1β levels circulating 
among IL-RA allele 2/2 carriers[63].
(2) IL-1β -31 CT polymorphism: A second plausible 
association was the decreased risk of GC in Asians 
carrying the haplotypes in the IL-1β ­31 CC promoter 
region. A decreased risk of GC among IL-1β ­31C carri­
ers was confirmed, but solely for Asian patients.
(3) IL-1β ­511 CT polymorphism in populations of 
different ethnic origin: Sub-analysis of various popu-
lations revealed a statistically significant association 
of stomach cancer with the IL-1β  polymorphism at 
promoter region ­511 CT in case­control studies based 
on populations (OR = 1.20, 95%CI: 1.00-1.43)[54]. The 
association is more consistent if only Caucasian popu­
lations are analyzed. Nevertheless, if taken together, the 
studies failed to show the association when stratified 
by ethnicities; IL-1β ­511 CT polymorphism according 
to tumor site: A significant association of IL-1β  ­511 
CT promoter region polymorphism was observed for 
stomach cancers when the tumor site (cardia vs non­
cardia) was taken into account, as well as for histology 
subtypes (intestinal or diffuse/mixed). The association 
was present both in the case of non-cardia GC (OR 
= 1.57, 95%CI: 1.06-2.31) as well as intestinal GC 
(respectively OR = 1.57, 95%CI: 1.06-2.31 and OR = 
1.24, 95%CI: 1.04-1.49)[54]; IL-1β +3954 CT polymor-
phism: Recently, Xu et al[54] performed a meta­analysis 
that was confirmed by that one by Xue et al[49]: There is 
a lack of association between IL-1β +3954 CT and GC 
risk.
(4) IL-10 haplotypes: IL-10 - regarded as the ma-
jor anti­inflammatory cytokine ­ will bind in form of 
homodimer its complex receptor, comprising four 
IL-10 receptor molecules, namely 2 IL-10 R1 and 2 
IL-10 R2. The binding induces STAT3 signaling via the 
phosphorylation of the cytoplasmic tails of IL-10 receptor 
1. IL-10 can inhibit the synthesis of pro-inflammatory 
cytokines; moreover it can block the function of nuclear 
factor-kappa B (NF-κB), and has other regulatory 
properties, e.g., JAK-STAT signaling[64]. The IL-10 gene 
is known to possess several SNPs, some in the distal 
region upstream of the coding gene (-1082 A/G, -819 
T/C) and a proximal one (the -592 A/C). Again, the com-
plex signaling and polymorphism of IL-10 can explain 
the contradictory results of the investigations.
(5) IL-10 -1082 AG polymorphism: A clear and curi-
ous dichotomy is evident, that is, when the studies were 
stratified according to Asian and non-Asian populations 
the observations reached opposite results. The Asian 
populations had greater risk of GC among IL-10 -1082 G 
carriers; conversely, there was a decreased risk among 
the non-Asian populations. Meta-analysis specific for 
IL-10 confirmed for Asian population the increased risk 
for intestinal type of gastric neoplasia in IL-10 -1082 
GG or GA haplotypes[53]; IL-10 -592 AC polymorphism: 
The -592 AC polymorphism failed to show any associ-
ation, as the odd ratios for GC were 0.93 and 0.94 
for homozygous and heterozygous population[55,65]; 
IL-10 -819 TC polymorphism: Little data is available 
for this polymorphism, confirming a protective effect 
in Asian populations. Nevertheless, it was not found to 
be associated with the reduced susceptibility to GC in 
individuals infected with H. pylori compared to uninfected 
controls. The IL-10 -819 TT genotype was found to be 
inversely correlated with the risk of the diffuse subtype, 
but not the intestinal subtype GC[51].
(6) IL-8 ­ 251 polymorphisms: Continuous expr­
ession of human IL-8 in transgenic mice (whereby IL-8 
is under the control of its own regulatory elements) 
increased tumorigenesis. Therefore, IL-8 may play an 
important role in gastrointestinal cancers. Elevated IL-8 
levels could be linked to a poor prognosis of neoplasia, 
henceforth its levels may be indicative of more aggres­
sive GCs.
Early data seemed to provide a possible association 
in GC as well[66]. A recent meta-analysis showed that the 
IL-8 -251 AA genotype in the Han population correlates 
with augmented risk of developing GC and AA genotype 
carriers appear to be more likely to develop GC in Asian 
populations. In addition, the IL-8 -251 AA genotype 
tended to be related to intestinal GC, but not with H. 
pylori infectious status[52]. There was no link between 
IL-8 polymorphisms and H pylori­related gastric malign­
ancies in non-Asian populations in all the meta-analyses 
examined[48,67].
(7) TNF-α polymorphism: Experimental studies have 
implicated TNF-α in processes that are involved in cancer 
progression, including promotion of metastatic behaviour 
and cancer associated cachexia[68,69]. The lack of TNF-α 
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in mice makes them resistant to carcinogenesis[70]. 
Clearly, such observation highlighted the link between 
genetic haplotypes for TNF-α and GC. 
TNF-α  -308 AG polymorphism: It was surprising 
to find a lack of association of this polymorphism with 
increased risk of GC, with only one exception: Non-Asian 
patients with distal cancer and homozygous for -308 
AA alleles; the association, moreover, appeared to exist 
for cancer of diffuse type only. However, this association 
was not confirmed when only good quality studies 
were taken into account, according to Persson et al[48]. 
Opposite conclusions were obtained by Zhu et al[59]; 
they recently analyzed all studies and concluded that, in 
the Caucasian populations, TNF-α rs1800629 (-308 AG) 
polymorphism indeed posed increased risk of GC. They 
used several genetic comparison models, i.e., A vs G, 
AA vs GG and AA vs GG/GA that gave OR respectively 
of 1.32, 1.76 and 1.62, all highly significant (A vs G: OR 
= 1.32, 95%CI: 1.12-1.56, P = 0.001; AA vs GG: OR = 
1.76, 95%CI: 1.37-2.26, P < 0.001; AA vs GG/GA: OR 
= 1.62, 95%CI: 1.27-2.07, P < 0.001)[59].
TNF-α  -238 polymorphism did not correlate with an 
increased cancer risk[48,58].
TNF-α 857 CT polymorphism: Reports on this topic 
are quite controversial. Cen et al[57] recently published his 
analysis of nine studies (all the reported ones); overall, 
they confirm that the TNF-α  857 CT polymorphism 
posed an elevated risk of GC solely among Asians; all 
four genetic models considered T vs C, TT vs CC, CT vs 
CC and TT vs CT gave consistent data, respectively with 
OR of 1.19, 1.44, 1.19 and 1.21 ( their statistical signifi-
cance being P = 0.002, P = 0.032, P = 0.008, P = 0.003 
respectively). 
TNF-β  252 AG polymorphism: A weak association 
with stomach malignancy was present in Asian popu-
lations, according to Xu et al[71]. Analysis by ethnicity 
revealed that the TNF-β 252 AG polymorphism correlated 
with a minor risk of GC (G vs A: OR = 1.10, 95%CI: 
1.02-1.19, P = 0.015) exclusively in Asians, not in 
Caucasians.
Dutch patients were analyzed for their polymorphism 
of IL­1β; they were found to carry lower risk of GC when 
heterozygous for either the IL-1B -511 and for the IL1β 
-31 TATA-box (genotype T/C)[72]. The EBV status of the 
patients did not affect this correlation and there could 
therefore be an early shared molecular mechanism in 
the progression of EBV-positive and negative GCs[72]. 
IL-6 polymorphism was not studied in relation to 
GC.
IL-6 knockout mice develop cancer less frequently[73]. 
It is therefore plausible that high IL-6 levels will promote 
tumorigenesis. Today, IL-6 is considered to be a relevant 
tumor-promoting factor also in humans. Indeed, it 
was correlated with glioma, lymphoma and melanoma 
at first, then with solid cancers such as breast and 
colorectal neoplasia (also ovarian and pancreatic), 
prostate, renal and colorectal cancers.
IL-6 is a critical factor during chronic inflammation, 
since it is required for the induction of effector Th17 
cells and inhibits the differentiation of regulatory T cells.
Stomach cells, however, lack IL-6 receptors; hence it 
cannot dimerize with the second receptor (gp 130) and 
the “classic signaling” is restricted to cells bearing both 
mIL-6R and gp130 on their surface. The latter is widely 
expressed, whilst mIL-6R expression is limited to some 
leukocytes, hepatocytes and cancer cells. It is therefore 
quite understandable that, as recently reported, a large 
meta-analysis on 105000 people established the lack 
of association of cancer risk with IL-6 polymorphism in 
Caucasians[74], despite the association which holds true 
for Africans.
Other cytokines
Gene polymorphism concerning cytokine different from 
those we have dealt with was recently considered in 
relation to the risk of developing GC. The studies are not 
sufficiently large so far; however it is worth reporting 
that a haplotypes of IL-17, IL-17F rs763780 TC, was 
significantly associated with GC development in Asian 
population[75].
IL­11 was taken into consideration in a single 
study[76]. A reduced risk for developing cancer at the 
gastric site was found for a polymorphism in the IL-4 
-590 CT gene in Caucasian but not in Asian populations. 
H pylori status was not taken into consideration in these 
studies[77].
Different results in different studies: The origin of the 
problem
IL­1β, TNF-α and the remaining dozens of cytokines 
are not the final executor of immune signaling or the 
resulting consequences in cancer promotion and spread. 
IL-1, TNF-α, together with bacterial antigens, LPS and 
several other signaling molecules bind their respective 
receptors on the cell membrane; a cascade of signals 
ensues upon receptor activation, which depends on the 
levels of Mg-ATP availability (in turn on Mg2+ concen­
tration in cells). Numerous different proteins are involved 
and regulate the signaling pathway, which finally 
results in the activation of a large family of DNA-binding 
proteins, the NF-κB family[78], which is a complex that 
regulates DNA transcription. NF-κB dimers are formed 
upon activation, stimulating the transcription of genes 
that encode cytokines, growth factors, chemokines, and 
anti­apoptotic factors[79]. However, some NF-κB dimers 
act by repressing, whilst others activate specific genes.
Cytokine polymorphism and Epstein-Barr virus-
associated GC
Worldwide, it was noted that Epstein-Barr virus (EBV) 
is present in a relevant proportion of malignant tumors 
of the stomach, with an incidence that is inversely 
proportional to that of GC. In the USA 16% to 18% of all 
stomach tumors were found EBV-associated (EBVaGC), 
in Southern China only 4.3%[80]; a survey of 101 
published papers reported that EBVaGC was evident in 
7.08% of intestinal type GC, while diffuse type GC had 
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an incidence of 9.82%[80]. Western and Central Asian 
countries had significantly more EBV positive cases than 
South-Eastern countries; in Europe, the frequency of 
EBV infection ranged from 1.7% in the United Kingdom 
to 40% in Poland[80].
An in vitro model of EBVaGC was used to demon-
strate that gastric cells, following EBV infection, have a 
high IL­1β expression, compared to EBV-negative gastric 
tumour cells. EBV-positive clones rapidly proliferated and 
were shown to be anchorage­independent in colony­
forming assays[81]. 
Since EBV infection is highly prevalent in all popu-
lations, whilst EBVaGC is quite rare, there were 
attempts to identify people who run an increased risk 
of developing GC. Polymorphisms of proinflammatory, 
as well as anti-inflammatory cytokines were studied, in 
particular in the promoter regions of IL-10 and TNF-α. 
For the latter, the allele -308 A (linked to high levels 
of TNF-α) had significantly higher frequency among 
EBVaGC individuals (23.3%) when compared to control 
subjects (12.0%, P < 0.05). The opposite was found 
in the case of the anti­inflammatory IL-10: The high­
producer allele (-1082 G) was found to be less frequent 
in EBVaGC patients in comparison to controls (6.3% vs 
3.0%, P < 0.05)[39,72].
The extreme complexities of all these interactions can 
explain the great variability in data when investigating 
the possible correlation between cytokine haplotypes 
and GC.
Gleanings on the usefulness of characterising H. pylori 
infected individuals for inflammatory haplotype
In addition to the complexity of this subject, the 
expectations created by the assertion that the host’s 
factors could contribute to the development of GC are 
disappointing, at least as far as the host’s inflammatory 
response to H. pylori infection is concerned. Once we get 
into details, we realize that in fact, the only determinant 
that really matters is the infection. The examination 
of the scientific literature on the cytokine subject has 
led to contradictory results: For each cytokine, the 
observations made by studying Caucasian people cannot 
be applied tout course to Asians; in certain cases, we get 
opposite results. In the different surveys, one can find 
association of determined haplotypes of inflammatory 
cytokines with an increased risk of GC, the opposite, or 
nil. Even the results of meta-analyses do not agree one 
another, according to whether studies are carried out by 
Chines or researchers from other nations. What does it 
mean? Is it because cytokines are not the final effectors, 
as they principally work on the long and winding road 
paved by the broad NF-κB family, which leads to GC 
(which means that the final response to inflammatory 
stimuli is far from hitting its target)? And what about 
the observations that people suffering from diseases 
far more inflammatory than chronic gastritis, such as 
rheumatoid arthritis, are likely protected from developing 
GC[82].
These observations may suggest that, if host factors 
are important in GC development, they probably 
have to be sought outside of the genes encoding the 
inflammatory cytokines.
NOT ALL PATIENTS ARE ALIKE: 
MOLECULAR BIOLOGY
The recent advances of molecular biological techniques 
allowed researchers to reach important insights into 
the oncogenesis mechanisms in gastric cancer. Besides 
the well-known pathogenic factor, H. pylori, several 
oncogenes and tumour suppressor genes, including 
cell cycle regulation genes involved in the growth and 
signal transduction pathways, have been identified[83-85]. 
In particular, alterations of genes involved in signalling 
pathways deregulation, patterns of aberrant DNA 
methylation, and chromosomal imbalances have been 
evidenced[86,87]. 
CHROMOSOMAL INSTABILITY 
Chromosomal instability (CIN) represents one of the 
main type of genomic instability observed in several 
neoplasms and it has been observed in a large cohort 
of patients with gastric cancer[88]. In particular, it is com-
monly detected in gastric malignant tumours and has 
been shown in up to 84% of gastrointestinal cancers[89]. 
CIN is characterized by chromosomal anomalies, 
including gain or loss of the complete chromosome 
(aneuploidy) and segments of chromosomes (loss of 
heterozygosity, amplifications and translocations)[90]. 
These abnormalities can impact on the oncogenes expr­
ession, tumour suppressor genes and other genes, as 
well as those involved in digestion, DNA repair, growth 
regulation, and control of cell cycle checkpoint[91-93]. The 
genetic mechanisms leading to CIN are not entirely 
known; H. pylori infection, smoking habit and some 
chemical substances such as nitrates and nitrites 
probably have an effect on inducing CIN; anyway their 
influence is actually uncertain[94]. On the other side, 
defects of chromosome segregation (CS), imperfect 
DNA damage response (DDR), anomalies in cell 
cycle regulators and telomere dysfunction have been 
identified as factors leading to numerical and structural 
chromosome alterations[95,96]. These carcinogens may 
alter chromosomes and the cytoskeleton promoting 
malignant modification[97].
CS alterations 
CS represents an important cellular process inducing 
the gastric epithelial cells division. Alterations of CS 
regulating mechanisms can cause DNA alterations or 
mitotic failures, leading to unfixable mutations as well 
as chromosomal number alterations[98]. In particular, the 
three recently proposed ways producing CIN are: Altered 
expression, polymorphisms and/or mutations of mitotic 
genes implicated in CS and the carcinogen activity upon 
47WJGO|www.wjgnet.com January 15, 2016|Volume 8|Issue 1|
Figura N et al . H. pylori  and gastric carcinoma
susceptible genetic background of individuals[99,100]. 
Many authors showed an aberrant expression of mitotic 
genes in CS. Moreover, the altered expression of BUB1 
protein (involved in controlling the spindle assembly 
checkpoint), was significantly increased in patients with 
diffuse type gastric adenocarcinoma, but not related to 
DNA ploidy[89]. Furthermore, in another study, BubR1 
and AURKB (proteins involved in the mitotic spindle 
assembly) expression resulted in association with a low 
risk of GC progression[101-103]. Aurora kinase A (AURKA/
STK15), a cell-cycle-regulated kinase with important 
role in microtubule formation and stabilization during 
CS, is often overexpressed in adenocarcinomas of the 
stomach, showing a suggestive new oncogenic pathway 
in GC[104].
Defective DDR
The mucosa of the stomach is continually subject to 
several environmental and intracellular mutagens, like 
ROS, H. pylori infection, nitrates, natrium, nitrites, and 
other water and food contaminants, able to induce DNA 
damage through different mechanisms[105,106]. Failure of 
the most important mechanisms of repair [nucleotide 
excision repair, base excision repair, mismatch repair 
(MMR) and recombination and/or DDR] may conduce 
to CIN and genetic aberrations, favouring carcinogenic 
process[107,108]. Several studies revealed differential 
mRNA expression of genes implicated in DNA repair 
process: ATM and HMGB1 (implicated in base excision 
repair), RAD23B (involved in nucleotide excision 
repair), UBE2V2, MUS81 [involved in resolving Holliday 
junctions (a branched DNA structure that contains four 
double-stranded arms joined together, considered the 
central intermediate in homologous recombination)], 
REV3L (involved in replication post-DNA damage), 
TP53, hHR23A and DDB1 (implicated in nucleotide 
excision repair), and XRCC1 (implicated in single­strand 
breaks repair) and MUTYH (implicated in base excision 
repair)[109-113]. 
H. pylori 
H. pylori has been shown to be able to induce DDR and 
double­strand breaks in gastric cancer with a mechanism 
of adhesion of bacteria that takes place between Lewis 
epitopes of the host and BabA adhesin[114]. Anyway, 
gastric mucosa cells can repair the DNA lesions induced 
by short-term infections. On the other side, prolonged 
infections induce saturation of repair mechanisms with 
a consequent ineffective DNA repair and malignant 
process begin. Moreover, continued infections lead to 
chronic inflammation, with resulting increase of muta-
genesis rate, oxidative-stress, down-regulation of MMR 
mechanisms, instability of genes and modulation of 
apoptosis by means of ROS formation[115-119]. Gastric 
inflammation represents an important host response 
able to induce H. pylori­related carcinogenesis[120]. 
In fact, in infected patients with IL-1β , TNF-α , IL-10 
and IL-8 polymorphisms, has been observed an in-
creased risk of distal gastric cancer progression[120,121]. 
Furthermore, different H. pylori strains seem to 
differently increase cancer risk by means of host 
genotypes[122] as these bacteria are able to communicate 
with their hosts. The equilibrium is determined both by 
host and bacterial features and may explain the reason 
why some H. pylori strains augment the carcinogenesis 
risk. For example, CagA positive strains promote severe 
gastritis and increase the pro­inflammatory cytokines’ 
level. This may lead to an environment favourable to the 
growth of other bacteria that can support inflammation 
and continually induce oxidative stress, increasing the 
risk for GC[1]. 
MICROSATELLITE INSTABILITY
Microsatellite instability (MSI) represents a genomic 
instability commonly detected in almost half of patients 
with GC. It is often observed in the Lynch syndrome 
(hereditary non­polyposis colorectal cancer) and in 
several sporadic cancers[123]. MSI phenotype is chara-
cterized by a high replication mistake rate leading 
to insertions and/or deletions of nucleotides within 
microsatellite repeats in neoplastic areas[123]. The MMR 
proteins are able to detect and repair these alterations, 
causing the dysfunction in MMR genes (MLH1 and 
MSH2) a MSI phenotype’s establishment, with a conse-
quently power off of cancer suppressor genes’ and loss 
of heterozygosity[124,125]. To this address, genes that 
are frequently modified induce cell cycle regulation and 
apoptosis (TGFβ  RII, RIZ, IGFIIR, TCF4, BAX, FAS, 
CASPASE5, BCL10 and APAF1) or are involved in the 
maintenance of genomic integrity (MSH6, MED1, MSH3, 
BLM, RAD50, ATR, and MRE11)[126]. 
DEREGULATION OF SIGNALLING 
TRASDUCTION PATHWAYS
The effects of genomic destabilization consist of an­
euploidy and gain or loss of the chromosome tracts 
involved in mRNA transcription. Genomic alterations can 
modify the normal cellular biology with a consequent 
neoplastic switch[127]. The clearly explored pathways 
that probably are involved in gastric pathogenesis are 
Wnt/betacatenin, extracellular signal-regulated MAPK, 
Hedgehog, Notch, NF-κB, TGF-β/BMP pathways, COX2/
PGE2, and tyrosine kinase signalling[128-143]. 
Finally, several studies evidenced that pathway 
deregulation involved in systemic inflammatory respo-
nse, such as IL-11/STAT1/gp130/STAT3, can induce a 
carcinogenic transformation too[144,145]. 
CONCLUSION
GC is a multifactorial disease. The main determinant, 
H. pylori infection, can be considered a sine qua non for 
GC development; however, despite almost all individuals 
who get GC are currently, or have been infected, it 
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is neither a necessary nor a sufficient condition. The 
intricacy of this topic resides in the proportion of infected 
people that will never get GC: 97% to 99%, according to 
the ethnic groups and geographic areas. Other remarks 
are unraveling the tangle: Almost all H. pylori strains 
from Japan and East Asia, the areas with the highest 
incidence of GC, are cagA+ and can be considered highly 
carcinogenic; in addition, the infection by certain cagA 
genotypes in western countries increases by far the risk 
of GC. 
At this point, one may wonder why these strains 
keep on infecting people. Following along with the evolu-
tion, only the characteristics that provide a selective 
advantage continue to be transmitted; this is a basic 
rule in eukaryotic and prokaryotic worlds. What is the 
benefit of being infected by carcinogenic strains? Why 
do they not disappear? People infected by strains that 
multiply the risk of GC by many times over, cannot be 
considered advantaged. Possible answers could reside in 
the following observations: (1) 97% to 99% of people 
never acquire GC; (2) the development of the sequence 
gastritis-metaplasia-dysplasia-cancer takes 40 years, or 
more, after the infection; which means that all women, 
as well as men, are fertile before the age at which GC 
occurs (many men also in old age, but they are less 
important, statistically speaking); hence, fertility is 
not affected by cancer development; and (3) women, 
who develop GC far less frequently than men, are the 
necessary genetic traits holders. Could these answers 
satisfy the laws of evolution (or distract them)? And how 
can the occurrence of GC in younger and younger ages 
be explained?
Apart from the complexity of this subject, the 
prospect created by the assertion that the host’s factors, 
such as the way the host reacts to infectious stimuli, 
may be important in the development of GC is discoura­
ging. Despite cytokines involved in the inflammatory 
response to infection, there are more than 30, just over 
half a dozen that have been examined in the relationship 
of H. pylori infection with GC and only haplotypes of 
IL-1 and TNF-α genes were found to possibly increase 
the GC risk, but only if the ethnicity of patients is not 
considered. Pursuing this line of inquiry makes us run 
the risk of sounding racist.
The hypothesis that the dissection of oncogenes and 
tumour suppressing genes could provide us with an 
answer to the question whether host factors are impor­
tant in GC development has only been partly proved. 
However, the conclusions have led us to a starting point, 
that is, they ended to indirectly confirm the pathogenic 
role of strains expressing CagA. The local and systemic 
levels of substances endowed with an increased muta­
genic potential, ROS, generated by immunocytes, and 
the consequent DNA damage are far higher when the 
infecting organisms harbour the cag PAI. 
In conclusion, as regards the development of GC, 
not all the H. pylori strains and patients are alike and 
not all share the same responsibility, but the only deter-
minant that really matters is the infection. 
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